Physician profile
Chad A Leep
NPI 1073741500
$925.85
in general payments reported to CMS, 2019-2025
21 companies · $99.37 in 2025
The $99.37 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $63.48 · 2021: $60.86 · 2022: $173 · 2023: $280 · 2024: $249 · 2025: $99.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $294.41 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.69 | 2021-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $59.04 | 2020-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $52.50 | 2023-2024 | Mounjaro, Jardiance |
| Amgen INC. | $47.40 | 2020-2024 | Otezla, Repatha |
| Novo Nordisk INC | $43.86 | 2021-2024 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $34.24 | 2023-2024 | Veozah |
| Antares Pharma, INC. | $32.98 | 2021-2022 | |
| Abbvie INC. | $32.64 | 2022 | |
| Janssen Pharmaceuticals, INC | $31.18 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $25.76 | 2025 | |
| Hikma Pharmaceuticals USA | $24.48 | 2022 | |
| Dexcom, INC. | $18.20 | 2021 | |
| Inari Medical, INC. | $17.64 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sanofi-Aventis U.S. LLC | $17.38 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.44 | 2025 | Lagevrio |
| Genentech USA, INC. | $14.69 | 2020 | |
| Exact Sciences Corporation | $14.10 | 2025 | The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $13.75 | 2023 | Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $13.44 | 2022 | |
| Gt Medical Technologies, INC | $13.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Leep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.